Core Viewpoint - The company, Steady Medical, has shown a significant recovery in profitability through both internal growth and acquisitions, with a notable increase in revenue and net profit in the first half of 2025 compared to the previous year [2][4]. Financial Performance - In the first half of 2025, Steady Medical achieved operating revenue of 5.296 billion yuan, a year-on-year increase of 31.31% [2][4]. - The net profit attributable to shareholders was 492 million yuan, up 28.07% year-on-year, while the net profit excluding non-recurring gains and losses was 461 million yuan, reflecting a growth of 40.9% [2][4]. - The company’s total expenses for the period were 1.874 billion yuan, an increase of approximately 27.4% year-on-year, with a period expense ratio of 35.39%, down about 1.08 percentage points from the previous year [9]. Business Segments - The medical segment generated operating revenue of 2.52 billion yuan, a year-on-year increase of 46.4%, while the consumer segment, represented by All Cotton Era, achieved revenue of 2.75 billion yuan, up 20.3% [5][6]. - The medical segment's operating profit margin reached 8.6%, an increase of 0.9 percentage points year-on-year, while the consumer segment's profit margin was 14%, up 1.2 percentage points [8]. Strategic Initiatives - The company has focused on controlling costs and enhancing operational efficiency, which has contributed to the recovery of profitability [8]. - The acquisition of Global Resources International, Inc. (GRI) for approximately 120 million USD has played a crucial role in the company's performance recovery since the fourth quarter of 2024 [4][5]. Dividend Policy - Steady Medical plans to distribute a cash dividend of 262 million yuan, accounting for 53.26% of the net profit for the period [3][9]. - Since its listing, the total cash dividends and buybacks will amount to 3.57 billion yuan, representing 100.33% of the net funds raised during the IPO [3][9].